CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (RP-2)Collaboration and Supply Agreement • June 3rd, 2020 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Delaware
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (RP-2) (the “Agreement”) is made and entered into effective as of the date signed by the last Party to sign below (the “Effective Date”) by and between Replimune Inc., a corporation organized under the laws of Delaware, having a place of business at 18 Commerce Way, Woburn, MA 01801 (the “Recipient”) and Bristol-Myers Squibb Company, having a place of business at 345 Park Avenue, New York, NY 10154 (“BMS”). The Recipient and BMS are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 3rd, 2020 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • California
THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of June 1, 2020 (the “Amendment Effective Date”), is entered into by and among REPLIMUNE GROUP, INC., a Delaware corporation, and each of its Subsidiaries (other than Excluded Subsidiaries and the MSC Subsidiary) (individually and collectively, “Borrower”), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (as defined below) (collectively, the “Lenders”), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent (in such capacity, “Agent”).
Replimune Inc Woburn, MA 01801 PERSONAL & CONFIDENTIALConsulting Agreement • June 3rd, 2020 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This letter of agreement and general release (“Agreement”) confirms our mutual agreement regarding the terms and conditions of your separation from employment with Replimune, Inc. (the “Company”). You and the Company agree as follows:
